An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients

Phase 2

Completed

Brief Summary: Eosinophils play a key role in the pathogenesis of eosinophilic oesophagitis. Therapies that suppress eosinophil recruitment and activation may give a benefit. Mepolizumab is a humanised monoclonal antibody against interleukin-5 (IL-5). This study will evaluate the ability of mepolizumab to decrease the recruitment and infiltration of eosinophils into the oesophagus, thereby reducing the inflammation and symptoms of EE (eosinophilic oesophagitis) in adult patients.

Recruitment & Eligibility

Inclusion Criteria

Document evidence/presence of Oesophagitis prior to commencing trial drug.
a)Histological evidence of Oesophagitis: greater than 20x eosinophils per high power field (X400) on histology of esophageal mucosal biopsy
b. at least one episode of dysphagia per week
c.Inadequate response to routine EE treatment
D. No other known causes of oesophagitis, or esophageal or generalized eosinophilia
Not pregnant or nursing

Exclusion criteria:

History of seasonal worsening of EE symptoms or requirement of Esophageal dilation.
Churg-Strauss Syndrome
Wegener's Granulomatosis
Lymphoma, hematological malignancy, advanced and metastatic solid tumors
Active H. pylori infection.
Any previous treatment with anti-hIL-5, anti-IgE monoclonal antibody or other biological agents.

Exclusion Criteria

Not provided

Primary Outcome Measures

Name	Time	Method
1. Reduction of eosinophils in the oesophagus 2. Safety and tolerability of mepolizumab

Secondary Outcome Measures

Name	Time	Method
1. Effect of treatment on symptoms, Eosinophil levels, and on inflammation biomarkers in oesophagus tissue and blood.

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial